BioLine RX (BLRX.TA) Stock Price
BioLine RX Price
BioLine RX (BLRX.TA) Stock | ISIN IL0011015182. BioLine RX operates in the Health sector.
BioLine RX stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of BioLine RX over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how BioLine RX stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing BioLine RX's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | BioLine RX Price |
|---|
BioLine RX Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
BioLine RX Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales BioLine RX generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue BioLine RX retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare BioLine RX's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares BioLine RX has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against BioLine RX's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
BioLine RX stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
BioLine RX Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
BioLine RX business model & stock analysis
BioLine RX SWOT Analysis
Strengths
BioLine RX Ltd possesses a strong technological expertise in the field of biopharmaceuticals. This enables the company to develop innovative and effective products.
The company has a diverse pipeline of drugs in various stages of development, providing a foundation for future growth and potential revenue streams.
BioLine RX Ltd has established strategic partnerships with renowned pharmaceutical companies, allowing for collaboration and access to additional resources and expertise.
Weaknesses
One of the main weaknesses of BioLine RX Ltd is its dependency on the success of its drug candidates. If any of the candidates fail in clinical trials, it can significantly impact the company's financial performance.
The company operates in a highly competitive industry where market entry barriers are significant. This poses a challenge for BioLine RX Ltd in gaining market share and establishing a strong presence.
BioLine RX Ltd may face resource constraints due to limited financial resources, which could limit its ability to fully capitalize on market opportunities.
Opportunities
The increasing demand for innovative biopharmaceutical products presents a significant opportunity for BioLine RX Ltd to expand its market presence and generate substantial revenue.
Collaborating with academic institutions and research organizations can provide access to cutting-edge research and development capabilities, enabling the company to stay ahead of competitors.
Expanding into emerging markets with unmet medical needs can allow BioLine RX Ltd to tap into new customer segments and diversify its revenue streams.
Threats
BioLine RX Ltd operates in a heavily regulated industry, which exposes the company to compliance and legal risks. Failure to comply with regulations can lead to penalties and reputational damage.
The emergence of new market entrants and competitors with significant resources and established market presence poses a threat to BioLine RX Ltd's market share and competitiveness.
Unforeseen challenges in the development and commercialization of drug candidates, such as unexpected side effects or delays in regulatory approvals, can negatively impact the company's financial performance and reputation.
BioLine RX Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
BioLine RX historical P/E ratio, EBIT multiple, and P/S ratio
BioLine RX annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
BioLine RX shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
BioLine RX shareholder structure
| % | Name |
|---|---|
6.25987% | |
0.00465% | |
% | |
% |
BioLine RX Executives and Management Board
Dr. Raphael Hofstein
(73)Director
Dr. Aharon Schwartz
(80)Chairman of the Board · since 2003
Mr. Philip Serlin
(60)Chief Executive Officer
Ms. Mali Zeevi
(41)Chief Financial Officer
Dr. Ella Sorani
(49)Vice President - Development
Frequently asked questions about BioLine RX
BioLine RX Ltd is a biopharmaceutical company focused on the development and commercialization of novel therapeutics. Their business model revolves around identifying promising technologies and advancing them through preclinical and clinical stages. By collaborating with leading academic institutions and strategic partners, BioLine RX aims to generate a diverse and innovative pipeline of products targeting unmet medical needs. This Israeli-based company is committed to leveraging its expertise in drug development and strategic relationships to bring novel therapeutics to market, thereby improving patients' lives and delivering value to its shareholders.
BioLine RX stock
BioLine RX Peer Group
BioLine RX FIGI
All fundamentals and in-depth analysis of BioLine RX
Our stock analysis for BioLine RX Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioLine RX Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.